Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

91.24 -4.60 (-4.80%)
Streaming Delayed Price Updated: 1:30 PM EDT, Sep 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Thera

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
AXSM FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
WHY: NEW YORK, NY - (NewMediaWire) - November 25, 2023 - Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM)... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
From The Rosen Law Firm PA
Via GlobeNewswire
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for Axsome Therapeutics's Future
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Axsome Therapeutics
Via Benzinga
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM
From The Rosen Law Firm, P.A.
Via Business Wire
3 Growth Stocks to Buy Right Now Without Any Hesitation
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
Can these promising growth stocks continue rising in value? 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Axsome's Strategy on Payer Coverage Slowly Pays Off, Depression Drug Sales Show Growth
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 m 
Via Benzinga
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Riding the Wave: 3 Stocks That Can 10X by 2025
Are you looking to invest in stocks with the potential to 10x? Here are three stocks that can 10x by 2025. 
Via InvestorPlace
Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now
Now, you can scoop up these future growth winners for a bargain. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Neither has performed well on the stock market this year. 
Via The Motley Fool
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 No-Brainer Stocks to Buy Right Now for Less than $100
You can start with a small investment and win big over time. 
Via The Motley Fool
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.